Matthew Ross Boyd

Executive

CA·SEDI

enGene Therapeutics Inc.

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

—

Latest filing published 19 Jun 2026 for enGene Therapeutics Inc., €216k. Read the official filing

Insider track record

Disclosed buys

Disclosed sells

Signal history

No signal scores available.

Matthew Ross Boyd: trading record in brief

Only one filing by Matthew Ross Boyd is known so far (19 June 2026): an option exercise, €216k, in enGene Therapeutics Inc. That is too little to draw conclusions. This summary is built from SEDI disclosures alone and does not predict where the share price will go.

Companies and markets linked to Matthew Ross Boyd

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

enGene Therapeutics Inc. (CA)

Declarations1 total

◇

Matthew Ross Boyd

5 - Senior Officer of IssuerExecutives16 Jun 2026enGene Therapeutics Inc.

350,000 CAD19SEDI ↗

200,000 shares@ CA$1.75100.0% of flowOptionsTSXSEDI:4737750

1 of 1 declaration

Matthew Ross Boyd

Insider track record

Matthew Ross Boyd: trading record in brief

Companies and markets linked to Matthew Ross Boyd

Related entities

Matthew Ross Boyd

Insider track record

Matthew Ross Boyd: trading record in brief

Companies and markets linked to Matthew Ross Boyd

Related entities